Skip to content
value.today

Soft Tissue Regeneration, Inc.

Formerly SOFT TISSUE REGENERATION LLC

Total raised
$25 M
7 rounds on record
Latest round
$4 M
Jun 2021
First round on record
Jul 2009
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Soft Tissue Regeneration, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2021$4 MNo. 7$2 to $10 million

Soft Tissue Regeneration, Inc.: Raise no. 7, Jun 2021

Investors in this round

36 investors had bought by the notice of Jun 25, 2021: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Convertible Promissory Notes
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffery A. Baird · Executive Officer
  • Kevin A Rocco · Executive Officer, Director
  • Daniel A Wagner · Director
  • Nicholas A Pachuda · Director
  • Paul A Hermes · Director
  • Richard A Emmitt · Director
  • Sacha A Levy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No amounts other than ordinary course employment compensation is being paid to officers and directors.”

Signed by Kevin A. Rocco, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 25, 2021. Read the notice at the SEC.

debt, optionsSEC
Jul 2019$4 MNo. 6$2 to $10 million

Soft Tissue Regeneration, Inc.: Raise no. 6, Jul 2019

Investors in this round

33 investors had bought by the notice of Sep 16, 2020: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$166,690 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kevin A. Rocco · Executive Officer, Director
  • Daniel A. Wagner · Director
  • Levy A. Sacha · Director
  • Paul A. Hermes · Director
  • Richard A. Emmitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin A. Rocco, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Sep 16, 2020. Read the notice at the SEC.

equitySEC
Mar 2018$1 MNo. 5Under $2 million

Soft Tissue Regeneration, Inc.: Raise no. 5, Mar 2018

Investors in this round

15 investors had bought by the notice of Mar 14, 2018: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kevin A Rocco · Executive Officer, Director
  • Daniel A Wagner · Director
  • Konstantine A Drakonakis · Director
  • Paul A Hermes · Director
  • Richard A Emmitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No payments other than ordinary course employment compensation is being paid to executive officers.”

Signed by Kevin A. Rocco, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 14, 2018. Read the notice at the SEC.

equitySEC
Nov 2016$1 MNo. 4Under $2 million

Soft Tissue Regeneration, Inc.: Raise no. 4, Nov 2016

Investors in this round

6 investors had bought by the notice of Dec 5, 2016: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$150,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kevin Rocco · Executive Officer, Director
  • Daniel Wagner · Director
  • Konstantine Drakonakis · Director
  • Richard Emmitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin Rocco, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 5, 2016. Read the notice at the SEC.

equity, optionsSEC
Nov 2013$8 MNo. 3$2 to $10 million

Soft Tissue Regeneration, Inc.: Raise no. 3, Nov 2013

Investors in this round

19 investors had bought by the notice of Nov 4, 2015: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $9 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$750,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph W Reilly · Executive Officer, Director, Promoter
  • Charles B Hart · Director
  • Daniel B Wagner · Director
  • Konstantine B Drakonakis · Director
  • Michael B Aronson · Director
  • Richard B Emmitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph W. Reilly, President and Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Nov 4, 2015. Read the notice at the SEC.

equity, optionsSEC
Sep 2011$4 MNo. 2$2 to $10 million

Soft Tissue Regeneration, Inc.: Raise no. 2, Sep 2011

Investors in this round

15 investors had bought by the notice of Mar 11, 2013: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$654,750 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph W Reilly · Executive Officer, Director, Promoter
  • Cato T Laurencin · Director, Promoter
  • Michael B Aronson · Director
  • Robert S Langer · Director
  • Russell E Tweeddale · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph W. Reilly, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 11, 2013. Read the notice at the SEC.

debt, optionsSEC
Jul 2009$3 MNo. 1$2 to $10 million

Soft Tissue Regeneration, Inc.: Raise no. 1, Jul 2009

Investors in this round

13 investors had bought by the notice of Jul 7, 2010: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$800,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph W Reilly · Executive Officer, Director, Promoter
  • Cato T Laurencin · Director, Promoter
  • Michael B Aronson · Director
  • Robert S Langer · Director
  • Russell E Tweeddale · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph W. Reilly, President and chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 7, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Soft Tissue Regeneration, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2021).

    SEC Form D · Jun 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2021

That is all the official record says: Soft Tissue Regeneration, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Soft Tissue Regeneration, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 36 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Soft Tissue Regeneration, Inc.
NameRoleNamed in
Jeffery A. BairdExecutive officerJun 2021
Kevin A RoccoExecutive officerJun 2021
Kevin A. RoccoExecutive officerSep 2020
Kevin RoccoExecutive officerDec 2016
Joseph W ReillyExecutive officerNov 2015
Daniel A WagnerDirectorJun 2021
Kevin A RoccoDirectorJun 2021
Nicholas A PachudaDirectorJun 2021
Paul A HermesDirectorJun 2021
Richard A EmmittDirectorJun 2021
Sacha A LevyDirectorJun 2021
Daniel A. WagnerDirectorSep 2020
Kevin A. RoccoDirectorSep 2020
Levy A. SachaDirectorSep 2020
Paul A. HermesDirectorSep 2020
Richard A. EmmittDirectorSep 2020
Konstantine A. DrakonakisDirectorJul 2019
Konstantine A DrakonakisDirectorMar 2018
Daniel WagnerDirectorDec 2016
Kevin RoccoDirectorDec 2016
Konstantine DrakonakisDirectorDec 2016
Richard EmmittDirectorDec 2016
Charles B HartDirectorNov 2015
Daniel B WagnerDirectorNov 2015
Joseph W ReillyDirectorNov 2015
Konstantine B DrakonakisDirectorNov 2015
Michael B AronsonDirectorNov 2015
Richard B EmmittDirectorNov 2015
Dane B MillerDirectorNov 2014
Cato T LaurencinDirectorMar 2013
Robert S LangerDirectorMar 2013
Russell E TweeddaleDirectorMar 2013
Joseph W ReillyPromoterNov 2015
Cato B LaurencinPromoterNov 2014
Cato T LaurencinPromoterMar 2013